Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
06/23/2022 | 377.25% | Goldman Sachs | $11 → $3 | Maintains | Neutral |
08/20/2021 | 536.33% | Benchmark | → $4 | Initiates Coverage On | → Speculative Buy |
Alterity Therapeutics Questions & Answers
The latest price target for Alterity Therapeutics (NASDAQ: ATHE) was reported by Goldman Sachs on June 23, 2022. The analyst firm set a price target for $3.00 expecting ATHE to rise to within 12 months (a possible 377.25% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Alterity Therapeutics (NASDAQ: ATHE) was provided by Goldman Sachs, and Alterity Therapeutics maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alterity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alterity Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.
While ratings are subjective and will change, the latest Alterity Therapeutics (ATHE) rating was a maintained with a price target of $11.00 to $3.00. The current price Alterity Therapeutics (ATHE) is trading at is $0.63, which is out of the analyst's predicted range.